Family history and women with ovarian cancer
Lanceley, Anne, Eagle, Zara, Ogden, Gemma, Gessler, Sue, Razvi, Khalil, Ledermann, Jonathan A. and Side, Lucy. (2012) Family history and women with ovarian cancer. International Journal of Gynecological Cancer, Vol.22 (No.2). pp. 254-259. ISSN 1048-891XFull text not available from this repository.
Official URL: http://dx.doi.org/10.1097/IGC.0b013e3182392714
Objective: The objective of the study was to determine how many women in an ovarian cancer (OC) study cohort had a family history (FH) recorded in their case notes and whether appropriate action was taken on the basis of that FH. Methods: This was a reviewof patient case-note data of women in a randomized controlled trial of follow-up after primary treatment for OC. Available case notes of 114 women recruited at 3 UK gynecologic cancer centers in a 2-year period between January 2006 and 2008 were examined. Case-note entries for the period from first hospital consultation to 2 years after completion of primary treatment were included. Outcome measures were (1) recording of an FH of cancer in the case notes, (2) whether appropriate action had been taken on the basis of the FH in those women with affected relatives, and (3) characterizing insufficient FH records. Results: Family history was not consistently recorded. Although FH was recorded in the majority of women, 14 women had no FH recorded. In 63 women, the FH was recorded as not significant, and in 15 cases, FH information was insufficient to complete a risk assessment. Twenty-two women had significant FH meeting criteria for specialist genetics referral. In 15 of these 22 cases, the relevant history suggestive of hereditary breast cancer and OC (due to BRCA1 or BRCA2 mutations) or Lynch syndrome had been documented, but no action was recorded, and its significance was not appreciated. Conclusions: These data indicate that training in recognizing relevant FH is needed for clinicians looking after women with OC. Research is necessary to determine the barriers in taking and interpreting an FH and to determine the optimal time for broaching FH issues during a woman's care pathway. This will improve the accuracy of FH recording and ensure families with OC have access to appropriate surveillance and genetic testing. Copyright © 2012 by IGCS and ESGO.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Journal or Publication Title:||International Journal of Gynecological Cancer|
|Publisher:||Lippincott Williams & Wilkins|
|Official Date:||February 2012|
|Page Range:||pp. 254-259|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)